 SAINT LAURENT, Quebec, Nov. 11, 2020 GLOBE NEWSWIRE -- IntelGenx Corp. TSX-V:IGX OTCQB:IGXT IntelGenx, a leading oral drug delivery company, today announced that the United States Patent and Trademark Office has issued U.S. Patent 10,828,254, entitled Oral film formulation for modulating absorption profile. The patent covers a novel oral film dosage technology platform for modulating the in vivo absorption profile of a sublingually- or buccally-administered active ingredient. 